The content on this site is intended for healthcare professionals only
Selecting the best tyrosine kinase inhibitors for chronic phase CML patients involves understanding various options, including first and second-generation TKIs. Factors like cost, accessibility, and patient preferences are crucial. Dosing strategies, especially for dasatinib, show that lower doses can improve outcomes. The concept of drug-free remission is significant, and quality of life remains a priority. Tailoring treatment to individual circumstances, including pregnancy, is essential for effective care.
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
SIOG 2024: Updates in haematology
Understanding the remaining unmet needs in a post ASCT NDMM setting
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Advancements in paediatric Acute lymphoblastic leukemia management
Choosing 1st line TKI Wisely in patients with CML
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
